30 closest matches · ranked by relevance
Adult Growth Hormone Deficiency · Hypothalamic-pituitary Disorders
Primary: Peak GH Level in Adult Patients With Hypothalamic-pituitary Disorders and 1-2 Pituitary Hormone Deficiency (PHD). — 0.9; 0.6; 0.7 ng/mL
Diagnosis of Adult Growth Hormone Deficiency (AGDH)
Primary: Receiver Operating Characteristic (ROC) Analysis on Peak GH (Growth Hormon) Concentrations — 2.36; 17.71 ng/mL
Growth Hormone Deficiency With Pituitary Anomalies
Primary: Co-primary Efficacy Variables: Percent Positive and Percent Negative Agreement of Macimorelin-GHST (MAC) With ITT — 55; 4; 19; 62 Participants
Acromegaly · Type 2 Diabetes Mellitus
Primary: Percentage With Growth Hormone (GH) Suppression to < 0.4 ng/ml — 0; 7; 8 Participants
Hypopituitarism
Primary: BOLD Signal Measured by Functional MRI Scan to Functional Connectivity Measured by fMRI
Adult Growth Hormone Deficiency
Primary: Percentage of Subjects Developing Binding Antibodies (BAbs) to Saizen® — 0 percentage of subjects
Dwarfism, Growth Hormone Deficiency
Primary: Number of Participants With Treatment Related Adverse Events. — 29 participants
Dwarfism, Pituitary
Primary: Change From Baseline in Serum Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) Levels at Week 4 — -2.04; -2.22; 1.38; 0.85 nanogram/millilter (ng/mL)…
Short Stature
Primary: Height Standard Deviation Score — -2.52; -1.57; -1.19; -1.09 standard deviation score
Heart Failure · Growth Hormone Deficiency · Ischemic Heart Disease
Primary: Peak VO2 — 14.5; 12.9 ml/kg/min
Acromegaly · Growth Hormone Deficiency · Pituitary Disease
Primary: Change in High-sensitivity C-reactive Protein — 2.93; 3.23; -0.36; 1.64 mg/liter
Adult Growth Hormone Deficiency
Primary: Number of Subjects Reporting Local Tolerability Events (Assessed by the Patient and Investigator) — 3; 3; 2; 1 Number of subjects with any symptom
Acromegaly
Primary: Percentage of Participants Diagnosed With Acromegaly — 5.8; 2.4 percentage of participants
Endocrine System Diseases
Primary: Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36 in Intent-to-Treat (ITT) Population — -1.29; 2.36 SDS
Growth Hormone Deficiency
Primary: Number of Participants Classified According to Insulin-like Growth Factor (IGF-I) Assessments — 11; 2; 4; 63 Participants
Polycystic Ovary Syndrome
Primary: Mean Overnight Growth Hormone Levels — 0.85; 0.84 ng/mL — p=0.918
Acromegaly
Primary: The Number of Patients Who Achieve a Trough Human Growth Hormone (hGH) Concentration of <2.5µg/L During the Last 12 Hours of the 23 Hour Profile Following Each Study…
Prader-Willi Syndrome
Primary: Body Composition — 51.2; 48.5; 52.1 percentage of body fat — p=<0.05
Growth Disorders · Insulin-Like Growth Factor-1 Deficiency
Primary: Height Velocity During the First Year - Intent to Treat (ITT)Population — 5.2; 6.9; 7.7 cm/yr — p=<0.0001
HIV Lipodystrophy
Primary: Overnight Mean Growth Hormone Secretion After 2 Weeks of Study Drug — 0.23; 0.07; 1.24 ng/mL — p=0.01
AIDS · HIV Infections
Primary: Change in Visceral Adipose Tissue Area From Baseline to 18 Months — -22; -4 centimeters squared — p=0.049
Hypopituitarism · Pituitary Insufficiency · Growth Hormone Deficiency, Adult
Primary: Clinically Significant Adverse Events — 2.58; 3.78; 4.0; 5.3 percentage of participants
Growth Hormone Disorder · Adult Growth Hormone Deficiency
Primary: Change in Truncal Fat Percentage (Week 34) — 0.49; -2.39; -1.17 Percentage of truncal fat — p==0.0090
Obesity
Primary: Aim 1: Stimulated Peak Growth Hormone Level — 5.2; 3.1; 1.9; 2.0 ng/ml
Obesity
Primary: HsCRP — -1.1; 0.5; -1.3; -0.3 mg/L
Growth Hormone, Recombinant · Fatty Liver
Primary: Intrahepatocellular Lipid (IHCL) Content — -0.63; 0.11 % change from baseline — p=0.6
Growth Hormone Deficiency · Endocrine System Diseases · Hormone Deficiency
Primary: Change From Baseline in Trunk Percent Fat at Week 38 — -1.68; 0.37 percent fat — p=<.0001
Growth Hormone Deficiency · Septo-Optic Dysplasia · Hypopituitarism
Primary: Change in Anthropometric Measures Over Time — 1.97; -0.61; 1.39; 1.22 Z-score
Traumatic Brain Injury
Primary: Functional Outcome 6 Months After Injury, as Measured by the Processing Speed Index — 82.5; 82.5 Processing speed index standardized scor
Fibromyalgia
Primary: Percentage of Participants With Less Than 11 Tender Points at Month 6 — 20; 22 Percentage of participants